Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2021

Liudahl SM, Betts CB, Sivagnanam S, Morales-Oyarvide V, da Silva A, Yuan C, et al. Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome. Cancer Discov. 2021;11(8):2014-2031.

Wang L, Liu D, Yung L, Rodriguez GD, Prasad N, Segal-Maurer S, et al. Co-Infection with 4 Species of Mycobacteria Identified by Using Next-Generation Sequencing. Emerg Infect Dis. 2021;27(11):2948-2950.

Miller DL, Ribeiro EA, Roy-Chowdhuri S, Illei PB, Siddiqui MT, Ali SZ. Renal medullary carcinoma involving serous cavity fluids: a cytomorphologic study of 12 cases. J Am Soc Cytopathol. 2021;10(2):187-196.

Showalter K, Spiera R, Magro C, Agius P, Martyanov V, Franks JM, et al. Machine learning integration of scleroderma histology and gene expression identifies fibroblast polarisation as a hallmark of clinical severity and improvement. Ann Rheum Dis. 2021;80(2):228-237.

Nam G, Singh K, Lopresti ML, Ouseph MM, Wang LJ, Wang Y. How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study. Technol Cancer Res Treat. 2021;20:15330338211035037.

Deng J, Thennavan A, Dolgalev I, Chen T, Li J, Marzio A, et al. ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancer. Nat Cancer. 2021;2(5):503-514.

Adib E, Nassar AH, Akl EW, Alaiwi SA, Nuzzo PV, Mouhieddine TH, et al. CDKN2A Alterations and Response to Immunotherapy in Solid Tumors. Clin Cancer Res. 2021;27(14):4025-4035.

Showers CR, Nuovo GJ, Lakhanpal A, Siegel CH, Aizer J, Elreda L, et al. A Covid-19 Patient with Complement-Mediated Coagulopathy and Severe Thrombosis. Pathobiology. 2021;88(1):28-36.

Hwang I, Tang D, Paik J. Oxidative stress sensing and response in neural stem cell fate. Free Radic Biol Med. 2021;169:74-83.

Pappa T, Ahmadi S, Marqusee E, Johnson HL, Nehs MA, Cho NL, et al. Oncogenic Mutations in PI3K/AKT/mTOR Pathway Effectors Associate with Worse Prognosis in BRAFV600E -Driven Papillary Thyroid Cancer Patients. Clin Cancer Res. 2021;27(15):4256-4264.